A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson's Disease

Kelvin L CHOU; Melissa M AMICK; Irene LITVAN; Laura MARSH; Tanya SIMUNI; Alexander I TRÖSTER; Ergun Y UC; Jason BRANDT; Richard CAMICIOLI; Karen FREI; Darren GITELMAN; Jennifer GOLDMAN; John GROWDON; Howard I HURTIG; Bonnie LEVIN

doi:10.1002/mds.23362

Back

A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson's Disease

Journal article

Peer reviewed

A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson's Disease

Kelvin L CHOU, Melissa M AMICK, Irene LITVAN, Laura MARSH, Tanya SIMUNI, Alexander I TRÖSTER, Ergun Y UC, Jason BRANDT, Richard CAMICIOLI, Karen FREI, …

Movement disorders, Vol.25(15), pp.2501-2507

2010

DOI: 10.1002/mds.23362

PMCID: PMC2978783

PMID: 20878991

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/2978783View

Open Access

Abstract

Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD.

Neurology

Biological and medical sciences

Medical sciences

Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases

Details

Title: Subtitle: A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson's Disease
Creators: Kelvin L CHOU - Departments of Neurology and Neurosurgery, University of Michigan, Ann Arbor, Michigan, United States
Melissa M AMICK - VA Boston Healthcare System and Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, United States
Irene LITVAN - Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, United States
Laura MARSH - Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, United States
Tanya SIMUNI - Parkinson's Disease and Movement Disorders Center and Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Alexander I TRÖSTER - Department of Neurology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, United States
Ergun Y UC - Department of Neurology, University of Iowa, Iowa City, Iowa, United States
Jason BRANDT - Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Richard CAMICIOLI - Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
Karen FREI - The Parkinson's and Movement Disorders Institute, Fountain Valley, California, United States
Darren GITELMAN - Departments of Neurology and Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Jennifer GOLDMAN - Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, United States
John GROWDON - Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, United States
Howard I HURTIG - Depratment of Neurology, University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
Bonnie LEVIN - Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, United States
Resource Type: Journal article
Publication Details: Movement disorders, Vol.25(15), pp.2501-2507
DOI: 10.1002/mds.23362
PMID: 20878991
PMCID: PMC2978783
NLM abbreviation: Mov Disord
ISSN: 0885-3185
eISSN: 1531-8257
Publisher: Wiley; Hoboken, NJ
Language: English
Date published: 2010
Academic Unit: Neurology
Record Identifier: 9984013920102771

Metrics

46 Record Views

135 Times Cited - Web of Science